logo-loader
Tissue Regenix Group PLC

Tissue Regenix shares rise as CellRight expands on Arthrex Inc relationship with European distribution deal

The AIM-listed firm said the agreement would allow Arthrex to distribute CellRight’s proprietary ‘BioRinse’ portfolio across Europe, with an initial focus on the UK

Knee bone in leg
CellRight provides osteobiologics for use in orthopaedic, spine and foot, and ankle procedures

Shares in Tissue Regenix Group PLC (LON:TRX) were on the up in mid-morning trading Tuesday after its subsidiary, CellRight Technologies, expanded its relationship with orthopaedic solutions company Arthrex Inc with a new pan-European distribution agreement.

The AIM-listed firm, which makes devices for regenerative medicine, said the agreement would allow Arthrex to distribute CellRight’s proprietary ‘BioRinse’ portfolio across Europe, with an initial focus on the UK.

READ: New Tissue Regenix CFO to step into role earlier than anticipated

The new deal, which will become effective immediately, is an extension of a previous US distribution agreement CellRight and Arthrex signed in March.

CellRight provides osteobiologics for use in orthopaedic, spine and foot, and ankle procedures to enhance healing of defects caused by trauma or disease.

READ: Tissue Regenix’s CellRight signs multi-year distribution agreement with Arthrex Inc

Steve Couldwell, chief executive of Tissue Regenix, said the agreement would allow the company to “exploit not only our ability to import our BioRinse bone portfolio into the UK facility, but also Arthrex' expansive distribution network”.

Shares were up 2% at 7.4p.

--Adds share price--

 

Quick facts: Tissue Regenix Group PLC

Price: £0.03

Market: AIM
Market Cap: £39.26 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

RNS

Unaudited Interim Results

1 week, 5 days ago

Appointment of CFO

3 weeks, 4 days ago

Directorate Change

on 08/01/2019

Holding(s) in Company

on 07/08/2019

Result of AGM

on 06/27/2019

Notice of AGM

on 06/04/2019

2 min read